U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer

Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy for use against lung , saying in draft guidance that it just cost too much to justify approval. But feels differently when it comes to using Opdivo against , today recommending it for approval without even extracting a price cut.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS